drugset / Trial / NCT02328482

Continuation Protocol to Protocol BBCO-001

NCT02328482

Phase 3 Completed 9 enrolled Bioblast Pharma Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

This will be a multi-center, randomized withdrawal, open-label, non-treatment concurrent control, parallel group study. Patients completing protocol BBCO-001 will be offered the opportunity to enter into this 12-month randomized withdrawal protocol.

Timeline

Start
2015-01
Primary completion
2017-10
Completion
2017-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Trehalose Small molecule 30 g Intravenous